Mauricio Z. Baptista, MD, PhD’s Post

VERZENIO (abemaciclib) is an oral, continuously dosed, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor indicated for the treatment of metastatic and high-risk early-stage HR+, HER2- breast cancer. At the American Society of Clinical Oncology (ASCO) 2024 meeting Eli Lilly and Company reported findings from the Phase III study (CYCLONE 2) of VERZENIO (abemaciclib) with ZYTIGA (abiraterone) in patients with mCRPC. DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: Unlock Expert Insights and In-Depth Analysis! https://lnkd.in/ggPcVGZ7 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

In addition to being asked, “Why CD24?” – I also get asked, “How is your lead drug candidate, PHST001, differentiated?” Due to the complex glycosylation patterns on CD24, not all antibodies against this target are created equal. We have engineered PHST001 to interact with all glyco-variants of CD24, which enables potent activity. And our preclinical data show that we are on the right track. Macrophage checkpoint inhibitors hold tremendous promise, and I believe that PHS001 can strike the right balance of safety and efficacy that is crucial to success. Thanks @PharmaShots for the opportunity to discuss the potential impact of PHST001, how it works, and the impact it could make on the field of cancer immunotherapy.

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/et-TjGuZ

Discover how personalised dosing can lead to improved outcomes in cancer care. Join experts in #oncology and #pharmacy to address key challenges and solutions. Don't miss Era of Personalized Medicine: What's Next? Personalised Dosing in Novel and Targeted Cancer Therapeutics, May 25 at 10:00 AM HKT. Register now: https://lnkd.in/eGZxBuKq

Did you know that only about 36% of patients diagnosed with lung cancer receive the right treatment? Access the AMCP Market Insights report, Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer, to discover how effective referral, utilization management, and advanced diagnostics can improve patient outcomes and reduce costs. Visit the AMCP Market Insights resource page to learn more: https://bit.ly/4efCk4W #managedcare #pharmacy #oncology

📰 #NSCLC | ASCO24: J&J's subQ Rybrevant matches efficacy, shrinks infusion time in Phase III trial "The PALOMA-3 trial, presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting, is testing the SC formulation of J&J's EGFR/MET-targeting bispecific antibody in 418 patients with EGFR-mutated, advanced or metastatic non-small-cell lung cancer (NSCLC) and exon 19 deletion or L858R mutations [...]" https://hubs.ly/Q02zY4Bq0 FirstWord Pharma

Watch our webinar with Amplia Therapeutics Limited, featuring CEO and MD Chris Burns. The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask Chris any questions about ATX that you may have. Key topics: - Data from recent trial - Why ovarian and pancreatic cancer? - What are the next key milestones and value drivers? - Where were the drugs discovered? Register here: https://hubs.la/Q02zctXZ0

Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer: Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors. #finance #pharmacy #lifesciences

Discover how basket trials are pivotal in oncology drug development, allowing for the simultaneous evaluation of therapies across multiple cancer types. This innovative approach, combined with cutting-edge Bayesian methods, enhances precision and efficiency, paving the way for more effective and faster cancer treatments. Read our latest blog by Yuan J. to learn how these advanced methodologies are shaping the future of oncology: https://hubs.ly/Q02HWVBw0 #Oncology #DrugDevelopment #BasketTrials #BayesianMethods #ClinicalTrials #PrecisionMedicine #CancerResearch #Pharma